You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK):重新獲得SHP2抑制劑的全球權利
格隆匯 07-04 18:48

格隆匯7月4日丨加科思-B(01167.HK)宣佈,AbbVie基於資產組合與戰略決策原因就雙方的許可及合作協議("該協議")發出終止通知,該協議涉及加科思根據該協議向AbbVie許可的SHP2抑制劑的全球開發及商業化。於該協議終止後,加科思將重新獲得之前授予AbbVie的該等SHP2抑制劑的全球權利,包括在全球範圍內與SHP2抑制劑相關的所有開發、商業化、生產、監管活動的決策權。加科思亦將擁有該等SHP2抑制劑在全球範圍內的銷售預訂權。雙方將合作在180天內有序交接該協議項下的責任。在交接期間,AbbVie將繼續報銷預先批准的開發計劃下的所有費用。

SHP2抑制劑與各種致癌驅動因子的抑制劑聯合使用時,在規避耐藥性方面發揮重要作用。目前,加科思擁有的前景廣闊的SHP2抑制劑(JAB-3312)正在進行IIa期全球試驗。加科思仍致力於推進其全球臨牀開發計劃,包括KRAS G12C抑制劑等多種聯合療法和各種腫瘤驅動因子抑制劑的靶向療法。JAB-3312聯合Glecirasib(加科思KRAS G12C抑制劑)的臨牀數據預計將於2023年下半年發佈。公司仍然有信心並致力於加快SHP2抑制劑的全球開發。

加科思是一家處於臨牀階段的生物技術公司,專注於開發針對癌症中無成藥性靶點的新藥。其強大的管道包括八項處於臨牀階段的臨牀資產及多項處於臨牀試驗(IND)啟用階段的資產。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account